MedTrace Logo

(Pakistan Diabetes Prevention Program PDPP)

NCT01530165 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1564

Last updated 2024-07-29

No results posted yet for this study

Summary

The Karachi-based Pakistan Diabetes Prevention Study aims to address key issues in the prevention of type 2 diabetes. Approximately 20,000 people From four communities will be screened for diabetes risk factors using a non-invasive diabetes risk-score system. Those found to be at increased risk will be given an oral glucose tolerance test. People who, after the oral glucose tolerance test, are identified as having prediabetes or normal but with risk factors such as raised BMI and/or history of hypertension will have the opportunity to take part in the Pakistan Diabetes Prevention Study lifestyle intervention. This consists of culturally adjusted preventive strategies focusing on diet and physical activity in real-life settings. Another important aspect of this trial will be to assess the impact of urban planning on the prevalence of obesity and diabetes.

Conditions

  • Prediabetic State & High Risk Individuals on the Basis of Diabetes Risk Score

Interventions

BEHAVIORAL

Life style intervention

The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat \<30 proportion of total energy, saturated fat \<10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up

Sponsors & Collaborators

Principal Investigators

  • Asma Ahmed, MRCP(UK) · The Aga Khan University Hospital

  • Jaweed Akhter, FRCP · The Aga Khan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-15
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01530165 on ClinicalTrials.gov